Corporate Counsel Weekly™ helps corporate lawyers get the big picture on the legal challenges facing corporations today. Practitioners can discover trends on the horizon and stay alert to the full...
By Manuel Baigorri, David Welch and Matthew Campbell
Oct. 16 — AbbVie Inc.'s board recommended that shareholders vote against a $52 billion takeover of Shire Plc, saying tax-rule changes would undermine the deal's rationale.
“Although the strategic rationale of combining our two companies remains strong, the agreed-upon valuation is no longer supported as a result of the changes to the tax rules and we did not believe it was in the best interests of our stockholders to proceed,” AbbVie Chief Executive Officer Richard A. Gonzalez said in an Oct. 16 statement.
Shire is considering the situation and will make a further announcement “in due course,” the company said in a statement.
AbbVie has also been concerned about the potential for more changes to U.S. laws, whether through executive branch action or legislation in Congress, that will increase future tax bills, people familiar with the matter have said.
The price AbbVie agreed to pay for Shire was the highest that it was able to offer, and the loss of some tax benefits and the related prospect of having to borrow more for the merger have eroded its attractiveness, the people said.
The merger would be the largest casualty yet of rules announced in September by the Treasury Department to make tax inversion deals more difficult.
In such transactions, U.S. companies seek to lower their tax bill by moving their legal address abroad, often after buying a foreign company. President Barack Obama's administration has said the rules are necessary to prevent the erosion of the U.S. corporate tax base.
The new rules have had some effect on other deals already. Medtronic Inc. said it will borrow $16 billion to finance its purchase of Covidien Plc instead of using cash it keeps overseas, and Salix Pharmaceuticals Ltd. and Auxilium Pharmaceuticals Inc. canceled planned inversions.
Treasury is contemplating a second set of rules that would limit companies from engaging in earnings stripping, a practice used by non-U.S.-based companies to load up U.S. operations with debt and effectively shift profits to countries with lower tax rates.
AbbVie began a comprehensive review of the merger after Treasury Secretary Jacob J. Lew announced the measures, people with knowledge of the matter said in September, including the prospect of borrowing as much as $7 billion more than it initially anticipated.
The rules, which apply to deals that close starting Sept. 22, include a prohibition on “hopscotch” loans that let companies access foreign cash without paying U.S. taxes, and impose new curbs on actions that companies can use to make such transactions qualify for favorable tax treatment.
Congress, which could impose even more stringent rules, is deadlocked on the issue and isn't scheduled to return to Washington until after the Nov. 4 elections.
Following AbbVie's statement, Senate Finance Committee Chairman Ron Wyden (D-Ore.) said he will keep pushing legislation to curb corporate inversions.
Wyden said Oct. 17 he would continue discussions about inversion-related measures and welcomed news that directors of AbbVie Inc. had abandoned a proposal to buy Dublin-based Shire.
“It's encouraging that companies like AbbVie, and their shareholders, recognize the strategic business value of remaining an American company,” Wyden said. “While it looks like the rush of inversions is slowing, we are continuing to examine the issue while focusing on fixing the root problem—our broken tax code. I'm committed to continued work across the aisle to close loopholes and get bipartisan, comprehensive tax reform done.”
Senate Democrats have been pushing legislation to further fight inversions. Talks have been stymied in part because of disagreements with Republicans about applying changes retroactively to companies that have already put inversions in place.
With assistance from Ian Katz in Washington and Oliver Staley in London.
To contact the reporters on this story: Manuel Baigorri in London at email@example.com, David Welch in New York at firstname.lastname@example.org and Matthew Campbell in London at email@example.com
To contact the editor responsible for this story: Mohammed Hadi at firstname.lastname@example.org
©2014 Bloomberg L.P. All rights reserved. Used with permission.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)